Impact BioMedical, Inc. - IBO STOCK NEWS

Impact BioMedical Inc. (NYSE: IBO) has announced the issuance of Canadian Patent #3,024,728 for its Linebacker™ technology platform. The patent, titled "Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders," covers novel enhanced phenolic compounds and pharmaceutical compositions for treating inflammatory diseases.

The Linebacker™ technology targets key inflammatory pathways, potentially reducing inflammation and providing symptomatic relief with fewer side effects compared to traditional anti-inflammatory medications. The patent includes a method for using Linebacker™ formulations to inhibit inflammatory responses in conditions such as arthritis, asthma, and inflammatory bowel disease.

This is the first Linebacker™ patent issued in Canada, with an expiration date in May 2037. CEO Frank D. Heuszel highlighted the significance of this achievement, noting that the Canadian Inflammatory Disease Treatment Market was estimated at $7B in 2022.

Impact BioMedical Inc. (NYSE American: IBO) has successfully completed its Initial Public Offering (IPO). The biotechnology company, focused on discovering, developing, and patenting innovative healthcare solutions, saw strong support from existing investors, who purchased over 30% of the IPO shares. This significant participation demonstrates confidence in the company's mission and potential.

Frank D. Heuszel, CEO of Impact BioMedical, expressed that the substantial involvement of existing investors underscores their belief in the company's work and its potential to make a meaningful impact on human health. The successful IPO marks an important milestone for Impact BioMedical as it continues its efforts in developing innovative healthcare solutions.

Impact BioMedical Inc. (NYSE: IBO) has announced the issuance of U.S. Patent No. 11,985,973 for its 3F™ technology platform, titled 'Insect Repelling Composition'. This patent, along with the previously granted U.S. Patent No. 11,246,310, covers natural insect repellent compositions derived from plant constituents and fragrances. These patents will expire in February 2039 and April 2040, respectively.

The 3F™ technology inhibits insect olfactory receptors, effectively 'blinding' insects to human presence. Potential applications include mosquito repellents and additives for detergents, shampoos, or lotions. This innovation addresses the global issue of vector-borne diseases, which account for 17% of all infectious diseases worldwide according to the WHO.

IBO CEO Frank D. Heuszel stated that this patent issuance demonstrates the company's successful business model in delivering unique proprietary technology for unmet healthcare needs. IBO is now accelerating discussions with potential partners to bring 3F™ to market in the US and globally.

Impact BioMedical Inc. (NYSE American: IBO) has unveiled its executive leadership team to spearhead the company's next phase of innovation and growth. The team includes:

Frank D. Heuszel as CEO, bringing experience in executive leadership, finance, and strategic planning. He previously served as CEO of DSS, Inc. and has a background in commercial banking.

Mark Suseck as COO, with experience in public and private healthcare companies. He previously served as COO of DSS BioHealth Holdings Inc. and CEO of Vivacitas Oncology Inc.

Todd Macko as CFO, also serving as CFO of DSS Inc. He brings over 25 years of public and corporate fiscal management experience.

The leadership team aims to advance Impact BioMedical's mission of discovering, developing, and patenting unique healthcare solutions.

Impact BioMedical Inc. (NYSE American: IBO) has successfully closed its initial public offering of 1,500,000 common stock shares at $3.00 per share. Trading began on the NYSE American Market on September 16, 2024, under the ticker symbol 'IBO'. The company granted underwriters a 45-day option to purchase up to 225,000 additional shares. Revere Securities, served as the sole book-running manager and received warrants to purchase up to 75,000 shares (86,250 if over-allotment is fully exercised) at $3.75 per share. The warrants are exercisable from nine months after the offering's commencement until the third anniversary. The SEC declared the registration statement effective on September 13, 2024.

Impact BioMedical Inc. (NYSE American: IBO), a company focused on human healthcare and wellness, has announced the pricing of its initial public offering. The company is offering 1,500,000 shares of common stock at $3.00 per share. Trading is expected to begin on the NYSE American Market on September 16, 2024, under the ticker symbol 'IBO'. The offering is set to close on September 17, 2024, subject to customary conditions. Impact has also granted underwriters a 45-day option to purchase an additional 225,000 shares. Revere Securities, is the book-running manager for the offering. The company has agreed to issue underwriter warrants to purchase up to 75,000 shares (86,250 if over-allotment is exercised), exercisable at 125% of the IPO price.